Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
| ▸ | APLNR | P35414 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304455 | 0.81 | ALDH1A1 (0.54) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3307189 | 0.81 | ALDH1A1 (0.46) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3305068 | 0.78 | ALDH1A1 (0.58) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3305331 | 0.75 | ALDH1A1 (0.55) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3301005 | 0.75 | KDM4E (0.55) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3301738 | 0.75 | ALDH1A1 (0.55) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3302437 | 0.73 | KDM4E (0.53) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL10079100 | 0.73 | ALDH1A1 (0.53) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL3301674 | 0.73 | ALDH1A1 (0.62) | HPGDCYP1A2KDM4EALDH1A1BLM | |
| SCHEMBL10059452 | 0.72 | ALDH1A1 (0.51) | HPGDCYP1A2KDM4EALDH1A1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | claimed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | claimed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | claimed |
| EP-1878428-A1 | 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES | Xiangya Hospital of Central South University (CN) | 2008-01-16 | — | — | EP | claimed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | claimed |
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | disclosed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | disclosed |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI JIAN | 2008-12-25 | — | — | US | disclosed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | REN, PTPRF, PPM1F | HPGD 666/4885CYP1A2 837/4885KDM4E 280/4885 |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | HPGD 366/4885CYP1A2 557/4885KDM4E 317/4885 |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | HPGD 366/4885CYP1A2 557/4885KDM4E 317/4885 |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | COL1A1, COL2A1, MMP1 | HPGD 366/4885CYP1A2 557/4885KDM4E 317/4885 |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | HPGD 366/4885CYP1A2 557/4885KDM4E 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.